Minerva Bets Big on Roluperidone for Schizophrenia's Silent Symptoms

BURLINGTON, Mass. – May 05, 2026 – In a pivotal move for both the company and millions of individuals affected by schizophrenia, Minerva Neurosciences has initiated a crucial confirmatory Phase 3 clinical trial for its lead drug candidate, roluperidone. The first patient was screened in March, marking the official start of a high-stakes journey that could lead to the first-ever approved treatment for the debilitating "negative symptoms" of schizophrenia.

The global trial, dubbed MIN-101C19, aims to provide the definitive evidence of efficacy that regulators demand, following a setback two years ago. With topline data not expected until the second half of 2027, Minerva is embarking on a multi-year, multi-million dollar gamble that positions roluperidone as the sole late-stage candidate specifically targeting this profound unmet medical need.

Targeting Schizophrenia's Silent Burden

While public perception of schizophrenia often focuses on its "positive" symptoms like hallucinations and delusions, a more insidious and disabling aspect of the disease are its "negative" symptoms. These include avolition (a severe lack of motivation), anhedonia (the inability to feel pleasure), social withdrawal, and blunted emotional expression. For up to 60% of patients, these persistent symptoms are the primary driver of long-term disability, severely impairing their ability to work, form relationships, and engage with the world.

Current antipsychotic medications, which primarily work by blocking dopamine receptors, are effective at controlling positive symptoms but do little to address negative ones. In some cases, their side effects can even mimic or worsen these very symptoms. This has created a vast treatment gap, leaving a significant patient population without effective therapeutic options.

"Patients often live with persistent negative symptoms such as avolition and anhedonia that remain even when positive symptoms of schizophrenia are controlled, driving long-term disability and functional impairment," said Dr. Remy Luthringer, Executive Chairman and CEO of Minerva Neurosciences, in a statement. He emphasized that the new trial is designed to evaluate roluperidone’s potential to "improve these core drivers of disability."

Roluperidone’s potential lies in its unique mechanism of action. It blocks serotonin, sigma, and other receptors but, crucially, does not directly interfere with the brain's dopamine pathways. This novel approach is believed to allow it to target primary negative symptoms without causing the motor and metabolic side effects common to traditional antipsychotics.

A Second Chance at Approval

This new Phase 3 trial represents a critical second chance for roluperidone. In February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Minerva's initial New Drug Application. The agency deemed that a single positive Phase 2b study was insufficient to establish effectiveness and requested an additional, robust confirmatory trial.

Minerva appears to have taken the FDA's feedback to heart. The MIN-101C19 trial was designed following "productive discussions" with the agency. The global study will enroll approximately 380 patients and is structured in two parts. Phase A, a 12-week placebo-controlled segment, will evaluate the drug's effect on negative symptoms as its primary goal. Phase B will then follow for an additional 40 weeks, comparing roluperidone's ability to prevent the relapse of positive symptoms against several commonly prescribed antipsychotics.

Significantly, the FDA has agreed that roluperidone can be studied as a monotherapy, a key differentiator from adjunctive treatments. This reflects earlier trial data suggesting patients' positive symptoms remained stable when they were switched to roluperidone alone. Success in this trial could provide the "substantial evidence of effectiveness" the FDA requires for a potential resubmission.

The High-Stakes Financial Gamble

Bringing a drug through a late-stage trial is a costly endeavor, and Minerva's financial filings reflect the beginning of this significant investment. The company's research and development expenses quadrupled in the first quarter of 2026 to $5.3 million compared to the previous year, a direct result of initiating the C19 trial.

While the company reported a staggering GAAP net loss of $125.4 million for the quarter, this figure is largely skewed by a non-cash expense of $109.4 million related to warrant liabilities. A clearer picture of the company's operational health is the non-GAAP adjusted net loss of $7.3 million.

With approximately $78.2 million in cash and marketable securities as of March 31, Minerva has what it projects to be at least a year's worth of funding. However, with the trial's primary data readout not expected until late 2027, the company's cash runway appears to fall short of the finish line. This suggests that further financing will be necessary to see the trial through to completion and fund a potential regulatory resubmission, adding another layer of pressure to the clinical execution.

A Crowded Field with a Unique Approach

While Minerva touts roluperidone as the "only late-stage drug candidate" for negative symptoms, the broader CNS landscape is not without competition. Other companies are also exploring novel mechanisms to address the full spectrum of schizophrenia symptoms. Notably, Karuna Therapeutics' KarXT, recently acquired by Bristol-Myers Squibb, has shown promise in reducing both positive and negative symptoms through a different, non-dopaminergic pathway targeting muscarinic receptors.

However, roluperidone's specific focus remains its key differentiator. It is being developed not as a broad-spectrum antipsychotic, but as a targeted monotherapy for the primary negative symptoms that leave patients so functionally impaired. Data presented at the Schizophrenia International Research Society 2026 Annual Congress also showed no significant safety or interaction issues when roluperidone was co-administered with the antipsychotic olanzapine, suggesting potential flexibility in future treatment paradigms.

For now, all eyes are on the MIN-101C19 trial. Its success or failure will not only determine the future of Minerva Neurosciences but could also reshape the treatment landscape for schizophrenia, offering a glimmer of hope for a silent, underserved, and long-suffering patient population. The journey to the 2027 data readout will be closely watched by patients, physicians, and investors alike.